{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T05:42:25Z","timestamp":1760593345252,"version":"build-2065373602"},"reference-count":44,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.hoc.2023.12.006","type":"journal-article","created":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T08:19:55Z","timestamp":1705911595000},"page":"421-440","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Role of Consolidation and Maintenance"],"prefix":"10.1016","volume":"38","author":[{"given":"Anupama D.","family":"Kumar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajai","family":"Chari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.hoc.2023.12.006_bib1","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1053\/j.seminoncol.2013.07.001","article-title":"Role of consolidation therapy in transplant eligible multiple myeloma patients","volume":"40","author":"Cavo","year":"2013","journal-title":"Semin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2023.12.006_bib2","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A\u00a0prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma","volume":"335","author":"Attal","year":"1996","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.hoc.2023.12.006_bib3","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma","volume":"348","author":"Child","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1016\/j.hoc.2023.12.006_bib4","doi-asserted-by":"crossref","first-page":"4647","DOI":"10.1182\/blood-2012-11-464503","article-title":"Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial","volume":"121","author":"Mellqvist","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.006_bib5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2012-02-408898","article-title":"Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma","volume":"120","author":"Cavo","year":"2012","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2023.12.006_bib6","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","article-title":"Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma","volume":"116","author":"Richardson","year":"2010","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.hoc.2023.12.006_bib7","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1182\/blood.V118.21.1872.1872","article-title":"Bortezomib, lenalidomide, and dexamethasone (VRD) consolidation and lenalidomide maintenance in frontline multiple myeloma patients: updated results of the IFM 2008 phase II VRD intensive program","volume":"118","author":"Roussel","year":"2011","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.hoc.2023.12.006_bib8","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.hoc.2023.12.006_bib9","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1200\/JCO.18.00685","article-title":"Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: results of the BMT CTN 0702 Trial","volume":"37","author":"Stadtmauer","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.hoc.2023.12.006_bib10","doi-asserted-by":"crossref","first-page":"8506","DOI":"10.1200\/JCO.2020.38.15_suppl.8506","article-title":"Long-term follow-up of BMT CTN 0702 (STaMINA) of postautologous hematopoietic cell transplantation (autoHCT) strategies in the upfront treatment of multiple myeloma (MM)","volume":"38","author":"Hari","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"32","key":"10.1016\/j.hoc.2023.12.006_bib11","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.1200\/JCO.21.01045","article-title":"Consolidation and maintenance in newly diagnosed multiple myeloma","volume":"39","author":"Sonneveld","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2023.12.006_bib12","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","volume":"7","author":"Cavo","year":"2020","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.006_bib13","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13045-018-0583-7","volume":"11","author":"Dimopoulos","year":"2018","journal-title":"J\u00a0Hematol OncolJ Hematol Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2023.12.006_bib14","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1182\/blood.2021010744","article-title":"Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results","volume":"138","author":"Roussel","year":"2021","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2023.12.006_bib15","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S1470-2045(21)00535-0","volume":"22","author":"Gay","year":"2021","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2023.12.006_bib16","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"issue":"10192","key":"10.1016\/j.hoc.2023.12.006_bib17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.hoc.2023.12.006_bib18","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.21.01935","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma","volume":"40","author":"Costa","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2023.12.006_bib19","doi-asserted-by":"crossref","first-page":"7275","DOI":"10.1182\/blood-2022-156730","article-title":"Outcomes of MRD-adapted treatment modulation in patients with newly diagnosed multiple myeloma receiving daratumumab, carfilzomib, lenalidomide and dexamethasone (Dara-KRd) and autologous transplantation: extended follow up of the master trial","volume":"140","author":"Costa","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.12.006_bib20","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1182\/blood-2021-147240","article-title":"Carfilzomib-Lenalidomide-Dexamethasone Consolidation in Myeloma Patients with a Positive FDG PET\/CT after Upfront Autologous Stem Cell Transplantation: A Phase II Study (CONPET)","volume":"138","author":"N\u00f8rgaard","year":"2021","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2023.12.006_bib21","first-page":"2261","article-title":"Future directions in maintenance therapy in multiple myeloma","volume":"10","author":"Holstein","year":"2021","journal-title":"J\u00a0Clin Med"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.006_bib22","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2011-06-357038","article-title":"The role of maintenance thalidomide therapy in multiple myeloma: MRC myeloma IX results and meta-analysis","volume":"119","author":"Morgan","year":"2012","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.hoc.2023.12.006_bib23","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.hoc.2023.12.006_bib24","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1182\/blood.V116.21.310.310","article-title":"Maintenance treatment with lenalidomide after transplantation for MYELOMA: final analysis of the IFM 2005-02","volume":"116","author":"Attal","year":"2010","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2023.12.006_bib25","doi-asserted-by":"crossref","first-page":"e431","DOI":"10.1016\/S2352-3026(17)30140-0","article-title":"Updated analysis of CALGB 100104 (Alliance): a randomised phase III study evaluating lenalidomide vs placebo maintenance after single autologous stem cell transplant for multiple myeloma","volume":"4","author":"Holstein","year":"2017","journal-title":"Lancet Haematol"},{"issue":"10","key":"10.1016\/j.hoc.2023.12.006_bib26","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous transplantation and maintenance therapy in multiple myeloma","volume":"371","author":"Palumbo","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"29","key":"10.1016\/j.hoc.2023.12.006_bib27","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","article-title":"Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis","volume":"35","author":"McCarthy","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.006_bib28","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(18)30687-9","article-title":"Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial","volume":"20","author":"Jackson","year":"2019","journal-title":"Lancet Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2023.12.006_bib29","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1182\/blood-2022-165376","article-title":"Defining the optimal duration of lenalidomide maintenance after autologous stem cell transplant - data from the myeloma XI trial","volume":"140","author":"Pawlyn","year":"2022","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2023.12.006_bib30","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1007\/s00277-019-03772-1","article-title":"Pomalidomide-based maintenance post-autologous hematopoietic cell transplantation in multiple myeloma: a case series","volume":"98","author":"Atieh","year":"2019","journal-title":"Ann Hematol"},{"issue":"6","key":"10.1016\/j.hoc.2023.12.006_bib31","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/bjh.18772","article-title":"Pomalidomide and dexamethasone until progression after first salvage therapy in multiple myeloma","volume":"201","author":"Garderet","year":"2023","journal-title":"Br J Haematol"},{"issue":"24","key":"10.1016\/j.hoc.2023.12.006_bib32","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","article-title":"Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/GMMG-HD4 trial","volume":"30","author":"Sonneveld","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"10168","key":"10.1016\/j.hoc.2023.12.006_bib33","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(18)33003-4","article-title":"Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"393","author":"Dimopoulos","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.006_bib34","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/ejh.13709","article-title":"Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study Group","volume":"108","author":"Gregersen","year":"2022","journal-title":"Eur J Haematol"},{"issue":"10","key":"10.1016\/j.hoc.2023.12.006_bib35","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/S1470-2045(21)00428-9","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2023.12.006_bib36","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s40262-016-0477-1","article-title":"Pharmacokinetics of daratumumab following intravenous infusion in relapsed or refractory multiple myeloma after prior proteasome inhibitor and immunomodulatory drug treatment","volume":"56","author":"Clemens","year":"2017","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"10.1016\/j.hoc.2023.12.006_bib37","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/leu.2013.335","article-title":"Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients","volume":"28","author":"Nooka","year":"2014","journal-title":"Leukemia"},{"issue":"17","key":"10.1016\/j.hoc.2023.12.006_bib38","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1200\/JCO.19.02515","article-title":"Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma","volume":"38","author":"Joseph","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.hoc.2023.12.006_bib39","doi-asserted-by":"crossref","first-page":"TPS8054","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS8054","volume":"39","author":"Shah","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2023.12.006_bib40","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/blood-2020-142913","volume":"136","author":"Krishnan","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.006_bib41","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S1470-2045(22)00693-3","article-title":"Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial","volume":"24","author":"Mina","year":"2023","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2023.12.006_bib42","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S1470-2045(22)00738-0","article-title":"Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial","volume":"24","author":"Dytfeld","year":"2023","journal-title":"Lancet Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2023.12.006_bib43","doi-asserted-by":"crossref","first-page":"7200","DOI":"10.1182\/blood-2022-159401","article-title":"Patient characteristics and survival outcomes of lenalidomide exposed non- refractory vs. lenalidomide refractory multiple myeloma patients in the honeur federated data network","volume":"140","author":"Hajek","year":"2022","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.hoc.2023.12.006_bib44","doi-asserted-by":"crossref","first-page":"8029","DOI":"10.1200\/JCO.2022.40.16_suppl.8029","article-title":"Biological correlative analyses and updated clinical data of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy, in patients with multiple myeloma (MM) and early relapse after initial therapy: CARTITUDE-2, cohort B","volume":"40","author":"van de Donk","year":"2022","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858823001739?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858823001739?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T05:18:14Z","timestamp":1760591894000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858823001739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0889858823001739"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2023.12.006","relation":{},"ISSN":["0889-8588"],"issn-type":[{"type":"print","value":"0889-8588"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of Consolidation and Maintenance","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2023.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}